-
摘要: 通过搜索Pubmed以及ClinicalTrials.gov数据库，包括ASCO会议摘要，回顾恩杂鲁胺的前瞻性临床试验及其结果：恩杂鲁胺对于去势抵抗性前列腺癌是一种有效的口服药，在化疗前和化疗后患者中均生存期获益，毒性温和，并获得NICE最终指南推荐用于治疗多西他赛化疗后的转移性去势抵抗性前列腺癌（mCRPC）患者。本文就其有关方面情况作一综述。Abstract: By searching Pubmed and ClinicalTrials.gov databases, including ASCO (American Society of Clinical Oncology) meeting abstract, prospective clinical trials and results of enzalutamide were reviewed. Enzalutamide is an effective oral therapy for castration-resistant prostate cancer. It may offer survival benefit before and following chemotherapy, and toxicity is mild. Moreover, the National Institute for Health and Care Excellence (NICE) issues final draft guidance recommends enzalutamide should be used for metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy. This review briefly introduces latest progress of enzalutamide for advanced prostate cancer.
-
-
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1):10-29.
[2] Huggins C, Hodges C V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate[J]. 1941. J Urol. 2002, 167(2 Pt 2):948-951; discussion 952.
[3] Huggins C. The hormone-dependent cancers[J]. JAMA, 1963, 186:481-483.
[4] Perlmutter M A, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer[J]. Rev Urol, 2007, 9(Suppl 1):S3-S8.
[5] Harris W P, Mostaghel E A, Nelson P S, et al. Androgen deprivation therapy:progress in understanding mechanisms of resistance and optimizing androgen depletion[J]. Nat Clin Pract Urol, 2009, 6(2):76-85.
[6] Crawford E D, Eisenberger M A, McLeod D G, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma[J]. N Engl J Med, 1989, 321(7):419-424.
[7] Eisenberger M A, Blumenstein B A, Crawford E D, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer[J]. N Engl J Med, 1998, 339(15):1036-1042.
[8] Crawford E D. Combined androgen blockade[J]. Urology, 1989, 34(4 Suppl):22-26; discussion 46-56.
[9] Walsh P C. Immediate versus deferred treatment for advanced prostatic cancer:initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group[J]. J Urol, 1997, 158(4):1623-1624.
[10] Messing E M, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer[J]. N Engl J Med, 1999, 341(24):1781-1788.
[11] [No authors listed]. Maximum androgen blockade in advanced prostate cancer:an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group[J]. Lancet, 2000, 355(9214):1491-1498.
[12] Petrylak D P, Tangen C M, Hussain M H, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J]. N Engl J Med, 2004;351(15):1513-1520.
[13] Tannock I F, de Wit R, Berry W R, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004, 351(15):1502-1512.
[14] de Bono J S, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial[J]. Lancet, 2010, 376(9747):1147-1154.
[15] Berthold D R, Pond G R, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study[J]. J Clin Oncol, 2008, 26(2):242-245.
[16] Berrieman H K, Lind M J, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy[J]? Lancet Oncol, 2004, 5(3):158-164.
[17] Sharma S V, Haber D A, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents[J]. Nat Rev Cancer, 2010, 10(4):241-253.
[18] Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription[J]. Nature, 2005, 437(7057):436-439.
[19] Kahl P, Gullotti L, Heukamp L C, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence[J]. Cancer Res, 2006, 66(23):11341-11347.
[20] Tran C, Ouk S, Clegg N J, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer[J]. Science, 2009, 324(5928):787-790.
[21] Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer[J]. Clin Cancer Res, 2011, 17(12):3876-3883.
[22] Scher H I, Beer T M, Higano C S, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer:a phase 1-2 study[J]. Lancet, 2010, 375(9724):1437-1446.
[23] Scher H I, Beer T M, Higano C S, et al. Phase Ⅰ-Ⅱ study of MDV3100 in castration-resistant prostate cancer (CRPC)[J]. J Clin Oncol, 2009, 27:abstract 151.
[24] Scher H I, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med, 2012, 367(13):1187-1197.
[25] Smith M R, Borre M, Rathenborg P, et al. Efficacy and safety of enzalutamide(ENZA) monotherapy in hormone-naive prostate cancer(HNPC)[J]. ASCO Meeting Abstracts, 2013, 31(15 Suppl):5001.
[26] Beer T M, Armstrong A J, Sternberg C N, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy[J]. N Engl J Med, 2014, Jun 1.[Epub ahead of print]
[27] Final appraisal determination-enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen[J]. National Institute for Health and Care Excellence Issue date:April 2014.
-
计量
- 文章访问数: 94
- PDF下载数: 71
- 施引文献: 0
下载: